This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Academy of Managed Care Pharmacy
March 31st – April 3rd 2025, Houston, TX
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

View poster
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane, MD,1 Andrea B. Barthel, MS,2 Chenxue Liang,2 Zhengfan Wang,2 Elizabeth S. Nagelhout,2 Lauren N. Strand, PhD, MS,3 Michael J. Doane, PhD,3 Regina Grebla, PhD3

View poster
Schizophrenia
Schizophrenia
POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

View poster
Schizophrenia
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2025 Alkermes, Inc. All rights reserved. MA-004230

This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants